VEGFA and hepatocellular carcinoma: A nationwide multicenter, retrospective cohort study comprising patients with advanced HCC, showed that first-line therapy with TACE plus ICI plus anti-VEGF antibody was associated with significantly longer OS (median, 22.6 vs. 15.9 months; HR, 0.63; P < 0.0001), PFS (median, 9.9 vs. 7.4 months; HR, 0.74; P < 0.0001), and ORR (41.2% vs. 22.9%; P < 0.0001) and acceptable safety profiles than treatment with ICI plus anti-VEGF antibody (143).